Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake in the RNA interference specialist. The big pharma company is also paying $100 million ...
It is the latest in a string of alliances announced by Boehringer in the NASH area in recent years, coming after earlier deals with Dicerna and MiNA Therapeutics – which both involved RNA-based ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback